DDInter405 DDInter1376
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Clofarabine {u} (Compound) resembles {v} (Compound) Adenosine monophosphate
Clofarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Clofarabine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Clofarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Clofarabine {u} (Compound) binds {v} (Gene) DCK
Clofarabine {u} (Compound) upregulates {v} (Gene) FAS
Clofarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Clofarabine {u} (Compound) downregulates {v} (Gene) ARL6IP1
Clofarabine {u} (Compound) causes {v} (Side Effect) Escherichia bacteraemia
Clofarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Clofarabine (Compound) resembles Adenosine monophosphate (Compound)
Clofarabine (Compound) resembles Nelarabine (Compound)
Clofarabine may lead to a major life threatening interaction when taken with Cladribine
Clofarabine (Compound) treats hematologic cancer (Disease)
Clofarabine (Compound) binds DCK (Gene)
Clofarabine (Compound) upregulates FAS (Gene)
Clofarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Clofarabine (Compound) downregulates ARL6IP1 (Gene)
Clofarabine (Compound) causes Escherichia bacteraemia (Side Effect)
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Enoxacin